Keir ST - Search Results

1

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA. Kurmasheva RT, et al. Among authors: keir st. Pediatr Blood Cancer. 2017 Apr;64(4):10.1002/pbc.26304. doi: 10.1002/pbc.26304. Epub 2016 Oct 27. Pediatr Blood Cancer. 2017. PMID: 27786412 Free PMC article.

2

Activity of temozolomide in the treatment of central nervous system tumor xenografts.

Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S, Catino JJ, Bigner DD, Schold SC Jr. Friedman HS, et al. Cancer Res. 1995 Jul 1;55(13):2853-7. Cancer Res. 1995. PMID: 7796412

3

Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD. Friedman HS, et al. Cancer Chemother Pharmacol. 1994;34(2):171-4. doi: 10.1007/BF00685936. Cancer Chemother Pharmacol. 1994. PMID: 8194169

4

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS. Hare CB, et al. Cancer Chemother Pharmacol. 1997;39(3):187-91. doi: 10.1007/s002800050558. Cancer Chemother Pharmacol. 1997. PMID: 8996518

5

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD, Modrich P. Friedman HS, et al. Cancer Res. 1997 Jul 15;57(14):2933-6. Cancer Res. 1997. PMID: 9230204

6

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.

Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS. Coggins CA, et al. Cancer Chemother Pharmacol. 1998;41(6):485-90. doi: 10.1007/s002800050771. Cancer Chemother Pharmacol. 1998. PMID: 9554593

7

Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.

Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, Friedman HS. Castellino RC, et al. Among authors: keir st. Cancer Chemother Pharmacol. 2000;45(4):345-9. doi: 10.1007/s002800050050. Cancer Chemother Pharmacol. 2000. PMID: 10755324

8

Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME, Bigner DD, Friedman HS. Patel VJ, et al. Clin Cancer Res. 2000 Oct;6(10):4154-7. Clin Cancer Res. 2000. PMID: 11051270

9

Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.

Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ. Friedman HS, et al. Among authors: keir st. Cancer Chemother Pharmacol. 2001 Nov;48(5):413-6. doi: 10.1007/s002800100358. Cancer Chemother Pharmacol. 2001. PMID: 11761460

10

O6-benzylguanine-mediated enhancement of chemotherapy.

Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME. Friedman HS, et al. Mol Cancer Ther. 2002 Sep;1(11):943-8. Mol Cancer Ther. 2002. PMID: 12481416

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters